<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729972</url>
  </required_header>
  <id_info>
    <org_study_id>NTMT-02-B</org_study_id>
    <nct_id>NCT04729972</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2</brief_title>
  <official_title>Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants With Macular Telangiectasia Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Lowy Medical Research Institute Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurotech Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF&#xD;
      implants in participants with Macular Telangiectasia Type 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular and Systemic Safety</measure>
    <time_frame>6 months</time_frame>
    <description>The number and severity of adverse events , systemic and ocular ,from baseline through six months post-implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best correct visual acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in visual acuity and retinal imaging with optical coherence tomography (OCT).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Macular Telangiectasia Type 2</condition>
  <arm_group>
    <arm_group_label>NT-501 CNTF Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from the NTMT-01 or NTMT-02 Studies with a CNFT implant in one eye will receive an implant in the fellow eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>NT-501 CNTF implant</intervention_name>
    <description>Single implantation of CNTF-secreting NT-501 device into one eye</description>
    <arm_group_label>NT-501 CNTF Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must understand and sign the informed consent&#xD;
&#xD;
          -  Must be medically able to undergo ophthalmic surgery for the NT-501 device insertion&#xD;
             and able to complete all required study procedures and visits&#xD;
&#xD;
          -  Participant must have received a NT-501 implant in one eye and have completed either&#xD;
             the multicenter Phase 1 or Phase 2 study of NT-501 in subjects with MacTel&#xD;
&#xD;
          -  In the eye that does not have a NT-501 implant, participant must have a positive&#xD;
             diagnosis of macular telangiectasia, type 2&#xD;
&#xD;
          -  Participant must have steady fixation in the foveal or parafoveal area and&#xD;
             sufficiently clear media for good quality photographs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant (positive pregnancy test at Visit 1 or intend to become pregnant during the&#xD;
             study)&#xD;
&#xD;
          -  Nursing (lactating)&#xD;
&#xD;
          -  Participant has evidence of ocular disorder(s) in the study eye of a severity that&#xD;
             could confound the interpretation of study results&#xD;
&#xD;
          -  Participant has a history or evidence of the following surgeries/procedures in the&#xD;
             study eye, as assessed at Visit 1, including: Submacular surgery, Vitrectomy, Retinal&#xD;
             detachment, Incisional glaucoma surgery, Trabeculectomy or trabeculoplasty, Cataract&#xD;
             surgery or laser-assisted in situ keratomileusis (LASIK) performed in the previous 6&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Eliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology. 2019 Apr;126(4):540-549. doi: 10.1016/j.ophtha.2018.09.041. Epub 2018 Oct 4.</citation>
    <PMID>30292541</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Telangiectasia Type 2</keyword>
  <keyword>CNTF</keyword>
  <keyword>Mactel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

